Literature DB >> 23095743

Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells.

Arindam Banerjee1, PengXu Qian, Zheng-Sheng Wu, Xiaoge Ren, Michael Steiner, Nicola M Bougen, Suling Liu, Dong-Xu Liu, Tao Zhu, Peter E Lobie.   

Abstract

Artemin (ARTN) has been reported to promote a TWIST1-dependent epithelial to mesenchymal transition of estrogen receptor negative mammary carcinoma (ER-MC) cells associated with metastasis and poor survival outcome. We therefore examined a potential role of ARTN in the promotion of the cancer stem cell (CSC)-like phenotype in mammary carcinoma cells. Acquired resistance of ER-MC cells to either ionizing radiation (IR) or paclitaxel was accompanied by increased ARTN expression. Small interfering RNA (siRNA)-mediated depletion of ARTN in either IR- or paclitaxel-resistant ER-MC cells restored cell sensitivity to IR or paclitaxel. Expression of ARTN was enriched in ER-MC cells grown in mammospheric compared with monolayer culture and was also enriched along with BMI1, TWIST1, and DVL1 in mammospheric and ALDH1+ populations. ARTN promoted mammospheric growth and self-renewal of ER-MC cells and increased the ALDH1+ population, whereas siRNA-mediated depletion of ARTN diminished these CSC-like cell behaviors. Furthermore, increased ARTN expression was significantly correlated with ALDH1 expression in a cohort of ER-MC patients. Forced expression of ARTN also dramatically enhanced tumor initiating capacity of ER-MC cells in xenograft models at low inoculum. ARTN promotion of the CSC-like cell phenotype was mediated by TWIST1 regulation of BCL-2 expression. ARTN also enhanced mammosphere formation and the ALDH1+ population in estrogen receptor-positive mammary carcinoma (ER+MC) cells. Increased expression of ARTN and the functional consequences thereof may be one common adaptive mechanism used by mammary carcinoma cells to promote cell survival and renewal in hostile tumor microenvironments.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23095743      PMCID: PMC3522252          DOI: 10.1074/jbc.M112.365163

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

Review 1.  TWISTing an embryonic transcription factor into an oncoprotein.

Authors:  S Ansieau; A-P Morel; G Hinkal; J Bastid; A Puisieux
Journal:  Oncogene       Date:  2010-04-12       Impact factor: 9.867

Review 2.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

Review 3.  Radioresistance in carcinoma of the breast.

Authors:  J K A Jameel; V S R Rao; L Cawkwell; P J Drew
Journal:  Breast       Date:  2004-12       Impact factor: 4.380

4.  CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells.

Authors:  M-Q Gao; Y-P Choi; S Kang; J H Youn; N-H Cho
Journal:  Oncogene       Date:  2010-03-01       Impact factor: 9.867

5.  Twist1-induced invadopodia formation promotes tumor metastasis.

Authors:  Mark A Eckert; Thinzar M Lwin; Andrew T Chang; Jihoon Kim; Etienne Danis; Lucila Ohno-Machado; Jing Yang
Journal:  Cancer Cell       Date:  2011-03-08       Impact factor: 31.743

6.  Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression.

Authors:  Farhad Vesuna; Ala Lisok; Brian Kimble; Venu Raman
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

7.  Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.

Authors:  Ryan Morrison; Stephen M Schleicher; Yunguang Sun; Kenneth J Niermann; Sungjune Kim; Daniel E Spratt; Christine H Chung; Bo Lu
Journal:  J Oncol       Date:  2010-10-12       Impact factor: 4.375

8.  Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.

Authors:  Koji Morimoto; Seung Jin Kim; Tomonori Tanei; Kenzo Shimazu; Yoshio Tanji; Tetsuya Taguchi; Yasuhiro Tamaki; Nobuyuki Terada; Shinzaburo Noguchi
Journal:  Cancer Sci       Date:  2009-03-09       Impact factor: 6.716

9.  ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma.

Authors:  Arindam Banerjee; Zheng-Sheng Wu; PengXu Qian; Jian Kang; Vijay Pandey; Dong-Xu Liu; Tao Zhu; Peter E Lobie
Journal:  Breast Cancer Res       Date:  2011-11-07       Impact factor: 6.466

10.  Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.

Authors:  Galatea Kallergi; Maria A Papadaki; Eleni Politaki; Dimitris Mavroudis; Vassilis Georgoulias; Sophia Agelaki
Journal:  Breast Cancer Res       Date:  2011-06-10       Impact factor: 6.466

View more
  22 in total

1.  LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.

Authors:  Keshuo Ding; Zhengsheng Wu; Xiaocan Li; Youjing Sheng; Xiaonan Wang; Sheng Tan
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

Review 2.  Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.

Authors:  Liangliang Xu; Chang Zou; Shanshan Zhang; Timothy Shun Man Chu; Yan Zhang; Weiwei Chen; Caining Zhao; Li Yang; Zhiyuan Xu; Shaowei Dong; Hao Yu; Bo Li; Xinyuan Guan; Yuzhu Hou; Feng-Ming Kong
Journal:  J Hematol Oncol       Date:  2022-07-07       Impact factor: 23.168

Review 3.  Neurotrophic Factors and Their Potential Applications in Tissue Regeneration.

Authors:  Nan Xiao; Quynh-Thu Le
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-11-26       Impact factor: 4.291

4.  GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer.

Authors:  Meghna Waghray; Malica Yalamanchili; Michele Dziubinski; Mina Zeinali; Marguerite Erkkinen; Huibin Yang; Kara A Schradle; Sumithra Urs; Marina Pasca Di Magliano; Theodore H Welling; Phillip L Palmbos; Ethan V Abel; Vaibhav Sahai; Sunitha Nagrath; Lidong Wang; Diane M Simeone
Journal:  Cancer Discov       Date:  2016-05-16       Impact factor: 39.397

5.  Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.

Authors:  Keshuo Ding; Arindam Banerjee; Sheng Tan; JunSong Zhao; Qian Zhuang; Rui Li; Pengxu Qian; Suling Liu; Zheng-Sheng Wu; Peter E Lobie; Tao Zhu
Journal:  J Biol Chem       Date:  2014-04-15       Impact factor: 5.157

Review 6.  Hematologic malignancies: newer strategies to counter the BCL-2 protein.

Authors:  Abdul Shukkur Ebrahim; Hussam Sabbagh; Allison Liddane; Ali Raufi; Mustapha Kandouz; Ayad Al-Katib
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-04       Impact factor: 4.553

7.  Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity.

Authors:  Yuzhu Hou; Hua L Liang; Xinshuang Yu; Zhida Liu; Xuezhi Cao; Enyu Rao; Xiaona Huang; Liangliang Wang; Lei Li; Jason Bugno; Yanbin Fu; Steven J Chmura; Wenjun Wu; Sean Z Luo; Wenxin Zheng; Ainhoa Arina; Jessica Jutzy; Anne R McCall; Everett E Vokes; Sean P Pitroda; Yang-Xin Fu; Ralph R Weichselbaum
Journal:  Sci Transl Med       Date:  2021-02-24       Impact factor: 17.956

8.  Prognostic significance of artemin and GFRα1 expression in laryngeal squamous cell carcinoma.

Authors:  Chaobing Gao; Xingwang Cheng; Xiaohong Li; Busheng Tong; Kaile Wu; Yehai Liu
Journal:  Exp Ther Med       Date:  2014-07-02       Impact factor: 2.447

9.  Prognostic significance of the expression of GFRα1, GFRα3 and syndecan-3, proteins binding ARTEMIN, in mammary carcinoma.

Authors:  Zheng-Sheng Wu; Vijay Pandey; Wen-Yong Wu; Shan Ye; Tao Zhu; Peter E Lobie
Journal:  BMC Cancer       Date:  2013-01-26       Impact factor: 4.430

Review 10.  A role for G-CSF and GM-CSF in nonmyeloid cancers.

Authors:  Alexander M Aliper; Victoria P Frieden-Korovkina; Anton Buzdin; Sergey A Roumiantsev; Alex Zhavoronkov
Journal:  Cancer Med       Date:  2014-04-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.